meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - breast cancer (mBC)
1
cervical cancer (CC)
classical Hodgkin lymphoma (cHL)
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">pembrolizumab based treatment</span>
<span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 1em;">others immune checkpoint inhibitors</span>
<span style="margin-left: 2em;">brentuximab vedotin <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DOR (1)
TRAE (any grade) (1)
TRAE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
TRAE leading to discontinuation (any grade) (1)
AE leading to death (grade 5) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Colitis TRAE (grade 3-4) (1)
Increased ALT TRAE (grade 3-4) (1)
Increase AST TRAE (grade 3-4) (1)
Hypothyroidism TRAE (grade 3-4) (1)
Hyperthyroidism TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Anaemia TRAE (grade 3-4) (1)
Pyrexia TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Thrombocytopenia TRAE (grade 3-4) (1)
Neutropenia TRAE (grade 3-4) (1)
Vomiting TRAE (grade 3-4) (1)
Constipation TRAE (grade 3-4) (1)
Paraesthesia TRAE (grade 3-4) (1)
Leucopenia TRAE (grade 3-4) (1)
Abdominal pain TRAE (grade 3-4) (1)
Nephritis TRAE (grade 3-4) (1)
Myocarditis TRAE (grade 3-4) (1)
Urticaria TRAE (grade 3-4) (1)
Eczema TRAE (grade 3-4) (1)
Acute kidney injury TRAE (grade 3-4) (1)
Infusion-related reactions TRAE (grade 3-4) (1)
Febrile neutropenia TRAE (grade 3-4) (1)
Pneumonia TRAE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for EEEE
brentuximab vedotin
pembrolizumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
brentuximab vedotin
pembrolizumab alone
brentuximab vedotin
---
NA
pembrolizumab alone
NA
---
pathologies: 73,232,233 - treatments: 359,575,577,576,869
result logic
×
Study list
